MNK

July 1, 2018 / Last updated : July 1, 2018 Benjamin Clark Pharmaceuticals

Mallinckrodt PLC Valuation – July 2018 $MNK

Mallinckrodt PLC does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the small size, insufficient earnings stability over the last ten years, and the poor dividend history.

August 28, 2016 / Last updated : August 28, 2016 Benjamin Clark Pharmaceuticals

Mallinckrodt PLC Valuation – August 2016 $MNK

Mallinckrodt PLC does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, the poor dividend history, and the high PEmg ratio.

July 26, 2015 / Last updated : July 26, 2015 Benjamin Clark Feature

5 Speculative and Overvalued Companies to Avoid – July 2015

By using the ModernGraham Valuation Model, I’ve selected five of the most overvalued companies reviewed by ModernGraham.

July 22, 2015 / Last updated : July 22, 2015 Benjamin Clark Pharmaceuticals

Mallinckrodt PLC Analysis – Initial Coverage $MNK

Mallinckrodt PLC does not qualify for either the Defensive Investor and the Enterprising Investor. The Defensive Investor is concerned with the short history as a stand alone company, lack of dividends, and the high PEmg and PB ratios.